TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Aldosterone Inhibition on Proteinuria in Patients With Progressive Renal Disease
Brief Summary: The purpose of this study is to examine whether the inhibition of aldosterone will result in lower excretion of protein via urine. The hypothesis is that if loss of protein is lowered, progression of renal disease with be slower than otherwise expected.


Options:
A: Arm Label: Group 1 - Patiromer; Type: EXPERIMENTAL; Interventions: Drug: Patiromer, Drug: Spironolactone | Arm Label: Group 2 - Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: Spironolactone | Intervention Type: DRUG; Name: Patiromer; Assigned to Arm(s): Group 1 - Patiromer | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group 2 - Placebo | Intervention Type: DRUG; Name: Spironolactone; Assigned to Arm(s): Group 1 - Patiromer, Group 2 - Placebo
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Eplerenone | Arm Label: 2; Type: NO_INTERVENTION; Interventions: Drug: Eplerenone | Intervention Type: DRUG; Name: Eplerenone; Assigned to Arm(s): 1, 2
C: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: BAY94-8862 | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: BAY94-8862 | Arm Label: Arm 3; Type: EXPERIMENTAL; Interventions: Drug: BAY94-8862 | Arm Label: Arm 4; Type: EXPERIMENTAL; Interventions: Drug: BAY94-8862 | Arm Label: Arm 5; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Arm 6; Type: ACTIVE_COMPARATOR; Interventions: Drug: Spironolactone | Intervention Type: DRUG; Name: BAY94-8862; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: BAY94-8862; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: BAY94-8862; Assigned to Arm(s): Arm 3 | Intervention Type: DRUG; Name: BAY94-8862; Assigned to Arm(s): Arm 4 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm 5 | Intervention Type: DRUG; Name: Spironolactone; Assigned to Arm(s): Arm 6
D: Arm Label: Spironolactone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Spironolactone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Spironolactone; Assigned to Arm(s): Spironolactone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Large, Randomised, Parallel-group, Controlled Trial, With Patients Randomly Allocated to Either N2O-containing (70% N2O in Oxygen [FiO2 0.3]) or N2O-free (70% Nitrogen in Oxygen [FiO2 0.3]).
Brief Summary: To investigate the safety of nitrous oxide (N2O) anaesthesia in patients with risk factors for coronary artery disease undergoing major surgery.


Options:
A: Arm Label: 70% Nitrous Oxide; Type: OTHER; Interventions: Other: Nitrous Oxide | Arm Label: No Nitrous Oxide; Type: OTHER; Interventions: Other: No Nitrous Oxide | Intervention Type: OTHER; Name: Nitrous Oxide; Assigned to Arm(s): 70% Nitrous Oxide | Intervention Type: OTHER; Name: No Nitrous Oxide; Assigned to Arm(s): No Nitrous Oxide
B: Arm Label: BIS group; Type: EXPERIMENTAL; Interventions: Device: Bispectral Index Monitor | Arm Label: MAC Alert; Type: ACTIVE_COMPARATOR; Interventions: Device: Electronic MAC alert | Intervention Type: DEVICE; Name: Bispectral Index Monitor; Assigned to Arm(s): BIS group | Intervention Type: DEVICE; Name: Electronic MAC alert; Assigned to Arm(s): MAC Alert
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Bispectral index protocol | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: End tidal anesthetic gas-guided | Intervention Type: BEHAVIORAL; Name: Bispectral index protocol; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: End tidal anesthetic gas-guided; Assigned to Arm(s): 2
D: Arm Label: BIS Monitor guided algorithm; Type: EXPERIMENTAL; Interventions: Device: BIS Monitor guided algorithm | Arm Label: Volatile anesthetic guided algorithm; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Volatile anesthetic guided algorithm | Intervention Type: DEVICE; Name: BIS Monitor guided algorithm; Assigned to Arm(s): BIS Monitor guided algorithm | Intervention Type: BEHAVIORAL; Name: Volatile anesthetic guided algorithm; Assigned to Arm(s): Volatile anesthetic guided algorithm

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Large, Randomised, Parallel-group, Controlled Trial, With Patients Randomly Allocated to Either N2O-containing (70% N2O in Oxygen [FiO2 0.3]) or N2O-free (70% Nitrogen in Oxygen [FiO2 0.3]).
Brief Summary: To investigate the safety of nitrous oxide (N2O) anaesthesia in patients with risk factors for coronary artery disease undergoing major surgery.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: Oxygen by mask | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Oxygen by mask | Intervention Type: OTHER; Name: Oxygen by mask; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Oxygen by mask; Assigned to Arm(s): 2
B: Arm Label: Oxygen therapy; Type: OTHER; Interventions: Other: Oxygen therapy | Arm Label: No oxygen therapy; Type: OTHER; Interventions: Other: No oxygen therapy | Intervention Type: OTHER; Name: Oxygen therapy; Assigned to Arm(s): Oxygen therapy | Intervention Type: OTHER; Name: No oxygen therapy; Assigned to Arm(s): No oxygen therapy
C: Intervention Type: DRUG; Name: Nitrous Oxide; Assigned to Arm(s): N/A
D: Arm Label: 70% Nitrous Oxide; Type: OTHER; Interventions: Other: Nitrous Oxide | Arm Label: No Nitrous Oxide; Type: OTHER; Interventions: Other: No Nitrous Oxide | Intervention Type: OTHER; Name: Nitrous Oxide; Assigned to Arm(s): 70% Nitrous Oxide | Intervention Type: OTHER; Name: No Nitrous Oxide; Assigned to Arm(s): No Nitrous Oxide

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Comparison of Oral Methylprednisolone Plus Azathioprine or Mycophenolate Mofetil for the Treatment of Bullous Pemphigoid
Brief Summary: To investigate the safety and efficacy of oral methylprednisolone combined with azathioprine or mycophenolate mofetil for the treatment of bullous pemphigoid.


Options:
A: Arm Label: Rituximab; Type: EXPERIMENTAL; Interventions: Drug: Rituximab | Arm Label: Corticotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: General Corticotherapy | Intervention Type: DRUG; Name: General Corticotherapy; Assigned to Arm(s): Corticotherapy | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): Rituximab
B: Intervention Type: DRUG; Name: Azathioprine or Mycophenolate mofetil; Assigned to Arm(s): N/A
C: Arm Label: Part A; Type: PLACEBO_COMPARATOR; Interventions: Drug: BIV009, Other: Placebo | Arm Label: Part B; Type: PLACEBO_COMPARATOR; Interventions: Drug: BIV009, Other: Placebo | Arm Label: Part C; Type: EXPERIMENTAL; Interventions: Drug: BIV009 | Arm Label: Part E; Type: EXPERIMENTAL; Interventions: Drug: BIV009 | Intervention Type: DRUG; Name: BIV009; Assigned to Arm(s): Part A, Part B, Part C, Part E | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Part A, Part B
D: Arm Label: Treatment Rituximab; Type: EXPERIMENTAL; Interventions: Drug: Rituximab | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): Treatment Rituximab

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: ARDSnet Protocol vs. the Open Lung Approach for the Ventilatory Management of Severe, Established ARDS: A Global Randomized Controlled Trial
Brief Summary: Many patients with Acute Respiratory Distress Syndrome or ARDS need breathing support that is provided by a machine called a ventilator or respirator. The purpose of this study is to find out if a new method of setting the ventilator for patients with severe ARDS is better than the standard, commonly used way of setting the ventilator.


Options:
A: Arm Label: EPVent; Type: EXPERIMENTAL; Interventions: Other: Esophageal-pressure guided mechanical ventilation | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Other: High PEEP mechanical ventilation | Intervention Type: OTHER; Name: Esophageal-pressure guided mechanical ventilation; Assigned to Arm(s): EPVent | Intervention Type: OTHER; Name: High PEEP mechanical ventilation; Assigned to Arm(s): Control
B: Arm Label: PHARLAP ventilation group; Type: EXPERIMENTAL; Interventions: Other: PHARLAP mechanical ventilation strategy | Arm Label: Control group ventilation; Type: ACTIVE_COMPARATOR; Interventions: Other: Control group mechanical ventilation strategy | Intervention Type: OTHER; Name: PHARLAP mechanical ventilation strategy; Assigned to Arm(s): PHARLAP ventilation group | Intervention Type: OTHER; Name: Control group mechanical ventilation strategy; Assigned to Arm(s): Control group ventilation
C: Arm Label: Minimal alveolar distension; Type: ACTIVE_COMPARATOR; Interventions: Device: Setting of positive end-expiratory pressure | Arm Label: Maximal alveolar distension; Type: EXPERIMENTAL; Interventions: Device: Setting of positive end-expiratory pressure | Intervention Type: DEVICE; Name: Setting of positive end-expiratory pressure; Assigned to Arm(s): Maximal alveolar distension, Minimal alveolar distension
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: Different Mechanical Ventilation Protocols | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Different Mechanical Ventilation Protocols | Intervention Type: OTHER; Name: Different Mechanical Ventilation Protocols; Assigned to Arm(s): 1, 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: ARDSnet Protocol vs. the Open Lung Approach for the Ventilatory Management of Severe, Established ARDS: A Global Randomized Controlled Trial
Brief Summary: Many patients with Acute Respiratory Distress Syndrome or ARDS need breathing support that is provided by a machine called a ventilator or respirator. The purpose of this study is to find out if a new method of setting the ventilator for patients with severe ARDS is better than the standard, commonly used way of setting the ventilator.


Options:
A: Arm Label: One Group; Type: N/A; Interventions: N/A
B: Intervention Type: OTHER; Name: Recruitment maneuver; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: Different Mechanical Ventilation Protocols | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Different Mechanical Ventilation Protocols | Intervention Type: OTHER; Name: Different Mechanical Ventilation Protocols; Assigned to Arm(s): 1, 2
D: Intervention Type: PROCEDURE; Name: Control Ventilation Strategy; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Antipsychotic Medication Extended Dosing Study
Brief Summary: In patients stabilized on their antipsychotic and demonstrating evidence of good clinical response, there will not be a significant change in symptoms if their medication is decreased to every 2 days rather than daily. This decrease in antipsychotic exposure will lead to a reduction in side effects, as well as improved subjective response to treatment.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Haloperidol, Risperidone (drug) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Haloperidol, Risperidone (drug) | Intervention Type: DRUG; Name: Haloperidol, Risperidone (drug); Assigned to Arm(s): 1, 2
B: Intervention Type: BEHAVIORAL; Name: integrated psychosocial treatment (behavior); Assigned to Arm(s): N/A
C: Intervention Type: PROCEDURE; Name: dosing; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: maintained antipsychotic treatment vs. stepwise drug discontinuation | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Other: maintained antipsychotic treatment vs. stepwise drug discontinuation | Intervention Type: OTHER; Name: maintained antipsychotic treatment vs. stepwise drug discontinuation; Assigned to Arm(s): 1, 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Reshaping Exercise Habits and Beliefs (REHAB): Pilot Testing of a Behavioral Intervention to Improve Mobility After Stroke
Brief Summary: Regular exercise has been demonstrated to improve muscle strength, balance, coordination as well as improve cardiovascular fitness levels and overall quality of life in stroke survivors. This study is designed to test the feasibility and effectiveness of a 12-week intervention to education and encourage stroke survivors to exercise following discharge from rehabilitation settings using a walking program and targeted functional activity homework.


Options:
A: Arm Label: Arm 1; Type: OTHER; Interventions: Behavioral: Exercise | Arm Label: Arm 2; Type: OTHER; Interventions: Other: Stroke education | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Arm 1 | Intervention Type: OTHER; Name: Stroke education; Assigned to Arm(s): Arm 2
B: Arm Label: Aerobic treadmill training; Type: EXPERIMENTAL; Interventions: Other: Aerobic treadmill training | Arm Label: Control (overground walking); Type: SHAM_COMPARATOR; Interventions: Other: Control (overground walking) | Intervention Type: OTHER; Name: Aerobic treadmill training; Assigned to Arm(s): Aerobic treadmill training | Intervention Type: OTHER; Name: Control (overground walking); Assigned to Arm(s): Control (overground walking)
C: Arm Label: Dual-task gait training; Type: EXPERIMENTAL; Interventions: Behavioral: Gait training | Arm Label: Single-task gait training; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Gait training | Intervention Type: BEHAVIORAL; Name: Gait training; Assigned to Arm(s): Dual-task gait training, Single-task gait training
D: Arm Label: Virtual Reality Therapy; Type: EXPERIMENTAL; Interventions: Other: Virtual Reality | Arm Label: Traditional Therapy; Type: ACTIVE_COMPARATOR; Interventions: Other: Traditional Therapy | Intervention Type: OTHER; Name: Virtual Reality; Assigned to Arm(s): Virtual Reality Therapy | Intervention Type: OTHER; Name: Traditional Therapy; Assigned to Arm(s): Traditional Therapy

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Reshaping Exercise Habits and Beliefs (REHAB): Pilot Testing of a Behavioral Intervention to Improve Mobility After Stroke
Brief Summary: Regular exercise has been demonstrated to improve muscle strength, balance, coordination as well as improve cardiovascular fitness levels and overall quality of life in stroke survivors. This study is designed to test the feasibility and effectiveness of a 12-week intervention to education and encourage stroke survivors to exercise following discharge from rehabilitation settings using a walking program and targeted functional activity homework.


Options:
A: Intervention Type: BEHAVIORAL; Name: Conventional UK Physical therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Increased intensity of UK conventional physical therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: UK conventional physical therapy plus functional strength training; Assigned to Arm(s): N/A
B: Arm Label: FAST+SAM; Type: EXPERIMENTAL; Interventions: Behavioral: FAST+SAM | Arm Label: FAST alone; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: FAST alone | Arm Label: SAM alone; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: SAM alone | Intervention Type: BEHAVIORAL; Name: FAST alone; Assigned to Arm(s): FAST alone | Intervention Type: BEHAVIORAL; Name: FAST+SAM; Assigned to Arm(s): FAST+SAM | Intervention Type: BEHAVIORAL; Name: SAM alone; Assigned to Arm(s): SAM alone
C: Arm Label: group 1: standard physiotherapy; Type: PLACEBO_COMPARATOR; Interventions: Procedure: standard physiotherapy | Arm Label: group 2: experimental physiotherapy; Type: EXPERIMENTAL; Interventions: Procedure: experimental physiotherapy | Intervention Type: PROCEDURE; Name: standard physiotherapy; Assigned to Arm(s): group 1: standard physiotherapy | Intervention Type: PROCEDURE; Name: experimental physiotherapy; Assigned to Arm(s): group 2: experimental physiotherapy
D: Arm Label: Arm 1; Type: OTHER; Interventions: Behavioral: Exercise | Arm Label: Arm 2; Type: OTHER; Interventions: Other: Stroke education | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Arm 1 | Intervention Type: OTHER; Name: Stroke education; Assigned to Arm(s): Arm 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multi-center, Multi-national, Randomized, Placebo-Controlled Trial of Azithromycin in Subjects With Cystic Fibrosis 6-18 Years Old, Culture Negative for Pseudomonas Aeruginosa
Brief Summary: This is a study to examine the safety, effect on lung function, and frequency of symptoms relating to cystic fibrosis during 24 weeks of treatment with the antibiotic azithromycin in 6-18 year-olds with CF who are not infected with Pseudomonas aeruginosa.


Options:
A: Arm Label: AZLI 75 mg 3 times a day (TID); Type: EXPERIMENTAL; Interventions: Drug: Aztreonam for Inhalation Solution (AZLI) | Arm Label: TIS 300 mg 2 times a day (BID); Type: ACTIVE_COMPARATOR; Interventions: Drug: Tobramycin Inhalation Solution (TIS) | Intervention Type: DRUG; Name: Aztreonam for Inhalation Solution (AZLI); Assigned to Arm(s): AZLI 75 mg 3 times a day (TID) | Intervention Type: DRUG; Name: Tobramycin Inhalation Solution (TIS); Assigned to Arm(s): TIS 300 mg 2 times a day (BID)
B: Arm Label: azithromycin liquid preparation; Type: EXPERIMENTAL; Interventions: Drug: Azithromycin | Arm Label: inert liquid preparation; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo control | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): azithromycin liquid preparation | Intervention Type: DRUG; Name: Placebo control; Assigned to Arm(s): inert liquid preparation
C: Arm Label: Active; Type: ACTIVE_COMPARATOR; Interventions: Drug: azithromycin 250 mg tablets | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo tablets | Intervention Type: DRUG; Name: azithromycin 250 mg tablets; Assigned to Arm(s): Active | Intervention Type: DRUG; Name: placebo tablets; Assigned to Arm(s): Placebo
D: Arm Label: azithromycin and TIS; Type: ACTIVE_COMPARATOR; Interventions: Drug: azithromycin, Drug: Tobramycin solution for inhalation | Arm Label: placebo and TIS; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo, Drug: Tobramycin solution for inhalation | Intervention Type: DRUG; Name: azithromycin; Assigned to Arm(s): azithromycin and TIS | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo and TIS | Intervention Type: DRUG; Name: Tobramycin solution for inhalation; Assigned to Arm(s): azithromycin and TIS, placebo and TIS

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multi-center, Multi-national, Randomized, Placebo-Controlled Trial of Azithromycin in Subjects With Cystic Fibrosis 6-18 Years Old, Culture Negative for Pseudomonas Aeruginosa
Brief Summary: This is a study to examine the safety, effect on lung function, and frequency of symptoms relating to cystic fibrosis during 24 weeks of treatment with the antibiotic azithromycin in 6-18 year-olds with CF who are not infected with Pseudomonas aeruginosa.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Azithromycin and Placebo | Arm Label: Azithromycin; Type: EXPERIMENTAL; Interventions: Drug: Azithromycin and Placebo | Intervention Type: DRUG; Name: Azithromycin and Placebo; Assigned to Arm(s): Azithromycin, Placebo
B: Arm Label: Active; Type: ACTIVE_COMPARATOR; Interventions: Drug: azithromycin 250 mg tablets | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo tablets | Intervention Type: DRUG; Name: azithromycin 250 mg tablets; Assigned to Arm(s): Active | Intervention Type: DRUG; Name: placebo tablets; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: Roxithromycin; Assigned to Arm(s): N/A
D: Arm Label: Clarithromycin; Type: EXPERIMENTAL; Interventions: Drug: Clarithromycin, Drug: VCD induction therapy | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: VCD induction therapy | Intervention Type: DRUG; Name: Clarithromycin; Assigned to Arm(s): Clarithromycin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: VCD induction therapy; Assigned to Arm(s): Clarithromycin, Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Indomethacin on the Progression of Alzheimer's Disease
Brief Summary: The purpose of this study is determine whether indomethacin is able to retard disease progression in patients with mild to moderate Alzheimer's disease.


Options:
A: Intervention Type: DRUG; Name: indomethacin; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Celecoxib (Celebrex); Assigned to Arm(s): N/A
C: Arm Label: A; Type: PLACEBO_COMPARATOR; Interventions: Drug: Celecoxib | Intervention Type: DRUG; Name: Celecoxib; Assigned to Arm(s): A
D: Arm Label: Aggrenox, Clopidogrel placebo, Micardis; Type: PLACEBO_COMPARATOR; Interventions: Drug: Aggrenox, Drug: Clopidogrel placebo, Drug: Micardis | Arm Label: Aggrenox placebo, clopidogrel,, Micardis; Type: PLACEBO_COMPARATOR; Interventions: Drug: Micardis, Drug: Aggrenox placebo, Drug: Clopidogrel | Arm Label: Aggrenox, clop placebo, micardis placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Aggrenox, Drug: Clopidogrel placebo, Drug: Micardis placebo | Arm Label: Aggrenox plcebo, clop, micardis placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Aggrenox placebo, Drug: Clopidogrel, Drug: Micardis placebo | Intervention Type: DRUG; Name: Aggrenox; Assigned to Arm(s): Aggrenox, Clopidogrel placebo, Micardis | Intervention Type: DRUG; Name: Aggrenox; Assigned to Arm(s): Aggrenox, clop placebo, micardis placebo | Intervention Type: DRUG; Name: Clopidogrel placebo; Assigned to Arm(s): Aggrenox, Clopidogrel placebo, Micardis | Intervention Type: DRUG; Name: Clopidogrel placebo; Assigned to Arm(s): Aggrenox, clop placebo, micardis placebo | Intervention Type: DRUG; Name: Micardis; Assigned to Arm(s): Aggrenox, Clopidogrel placebo, Micardis | Intervention Type: DRUG; Name: Micardis; Assigned to Arm(s): Aggrenox placebo, clopidogrel,, Micardis | Intervention Type: DRUG; Name: Aggrenox placebo; Assigned to Arm(s): Aggrenox placebo, clopidogrel,, Micardis | Intervention Type: DRUG; Name: Aggrenox placebo; Assigned to Arm(s): Aggrenox plcebo, clop, micardis placebo | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Aggrenox placebo, clopidogrel,, Micardis | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Aggrenox plcebo, clop, micardis placebo | Intervention Type: DRUG; Name: Micardis placebo; Assigned to Arm(s): Aggrenox, clop placebo, micardis placebo | Intervention Type: DRUG; Name: Micardis placebo; Assigned to Arm(s): Aggrenox plcebo, clop, micardis placebo

Answer: A